Intellia's rivals have hit speed bumps, too. CRISPR Therapeutics, which just won the first U.S. approval of a CRISPR-based medicine in December, restructured some of its research and, according to Fierce Biotech, recently laid off some staff. Editas Medicine, another early CRISPR company, cut jobs one year ago after a series of setbacks and executive departures.